Proapoptotic and Growth-Inhibitory Role of Angiotensin II Type 2 Receptor in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats In Vivo
The DOI matches its Crossref record.
Abstract
Abstract—Angiotensin type 2 (AT 2) receptors for angiotensin II suppress cell growth and induce apoptosis in vitro, but their role is poorly defined in vivo. We reported that transient induction of smooth muscle cell (SMC) apoptosis precedes DNA synthesis inhibition and aortic hypertrophy regression in spontaneously hypertensive rats treated with the AT 1 antagonist losartan or the converting-enzyme inhibitor enalapril. Although both drugs are equipotent in reducing SMC number, apoptosis occurs significantly earlier with losartan than enalapril. To examine the role of AT 2 receptors in this model, spontaneously hypertensive rats were given valsartan, an AT 1 antagonist, or enalapril, in combination or not with the AT 2 antagonist PD123319 for 1 or 2 weeks. Control rats received vehicle. Systolic blood pressure was reduced similarly by valsartan and enalapril but it was not significantly affected by PD123319. Angiotensin II plasma levels were increased (6-fold) with valsartan and reduced (80%) with enalapril but unaffected by PD123319. Valsartan significantly increased internucleosomal DNA fragmentation indicative of apoptosis at 1 week only (2.7-fold) and significantly reduced aortic mass (18%), SMC number (33%), and DNA synthesis (24%, measured by 3 H-thymidine incorporation) at 2 weeks. These valsartan-induced changes were prevented by PD123319. In contrast, enalapril-induced DNA fragmentation (2-fold increase at 2 weeks) was not affected by PD123319. PD123319 given alone did not affect growth or apoptosis. AT 1 and AT 2 receptor mRNAs were detected in the aorta by reverse transcription–polymerase chain reaction. Together, these results provide the first evidence that AT 2 receptors mediate vascular mass regression by stimulating SMC apoptosis in vivo, an effect seen during AT 1 receptor blockade but not during converting-enzyme inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Oparil, S., Zaman, M. A., & Calhoun, D. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-9-200311040-00011 · Cited by 680
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
The renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
Postischemic Revascularization: From Cellular and Molecular Mechanisms to Clinical Applications
Silvestre, J.-S., Smadja, D. M., & Lévy, B. I. (2013) · Physiological Reviews · doi:10.1152/physrev.00006.2013 · Cited by 255
Schiffrin, E. L., & Touyz, R. M. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00262.2004 · Cited by 253
Self-citationAT2 receptors: Functional relevance in cardiovascular disease
Jones, E. S., Vinh, A., McCarthy, C. A., Gaspari, T. A., & Widdop, R. E. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.009 · Cited by 237
“Importantly, this AT2R-mediated vascular anti-hypertrophic effect was not simply a consequence of sartan-induced BP-lowering, as simultaneous PD123319 administration had no further influence on BP in these studies (Tea et al., 2000; Jones et al., 2004).”
BackgroundMethodResultInfluentialAngiotensin AT2 receptors: cardiovascular hope or hype?
Widdop, R. E., Jones, E. S., Hannan, R. E., & Gaspari, T. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705448 · Cited by 223
“Ang II is also reported to stimulate NO release directly in isolated blood vessels (Seyedi et al., 1995; Thorup et al., 1998; Thorup et al., 1999); a component of which is mediated by AT2R.”
BackgroundMethodMolecular mechanisms of angiotensin II-induced vascular injury
Ruiz-Ortega, M., Ruperez, M., Esteban, V., & Egido, J. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0014-0 · Cited by 163
“In spontaneously hypertensive rats, AT1 blockade caused VSMC apoptosis that was attenuated by AT2 antagonism [ 5 ].”
BackgroundThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Ikeda, S., Shinohara, K., Kashihara, S., Matsumoto, S., Yoshida, D., Nakashima, R., Ono, Y., Nishihara, M., Katsurada, K., & Tsutsui, H. (2023) · Hypertension Research · doi:10.1038/s41440-022-01091-z · Cited by 20
Metadata
- Authors
- Tea, B.-S., Der Sarkissian, S., Touyz, R. M., Hamet, P., & deBlois, D.
- Venue
- Hypertension
- Published
- 2000-05
- Volume
- 35
- Issue
- 5
- Pages
- 1069-1073
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2145091966
- Cited by
- 95
- References
- 0
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.